EGFR is a transmembrane protein that promotes cell proliferation when activated.1 Deletion of exons 2-7 in the extracellular domain of EGFR results in a mutant form of the receptor, EGFRvIII, that cannot bind its ligands but is constitutively active with continuous downstream signaling and impaired degradation.2
It is estimated that up to 60% of EGFR-amplified glioblastomas have the EGFRvIII mutation, which is associated with poor prognosis and shorter survival. EGFRvIII is exclusively expressed in tumor cells, making it an attractive therapeutic target.2
Learn more about modalities targeting EGFRvIII:
Search our clinical trials.
EGFR: epidermal growth factor receptor.
1. National Center for Biotechnology Information. EGFR epidermal growth factor receptor [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/1956. Accessed 4/5/2019.2. Keller S, Schmidt MHH. EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for effective treatment. Int J Mol Sci. 2017;18(6):E1295.